Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.

@article{Martz2012TargetingTH,
  title={Targeting the hinge glycine flip and the activation loop: novel approach to potent p38$\alpha$ inhibitors.},
  author={Kathrin E Martz and A. Dorn and B. Baur and V. Schattel and M. Goettert and S. Mayer-Wrangowski and D. Rauh and S. Laufer},
  journal={Journal of medicinal chemistry},
  year={2012},
  volume={55 17},
  pages={
          7862-74
        }
}
The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines. Small molecule p38 inhibitors suppress the production of these cytokines. Therefore p38 is a promising drug target for novel anti-inflammatory drugs. In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38α MAP kinase inhibitors. Previously reported dibenzepinones and dibenzoxepines were chemically modified by introduction of functional groups or… Expand
A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors
TLDR
A complete overview of the available crystal structures of this protein in complex with ATP‐site type I inhibitors is presented to support drug discovery programs aimed at identifying new immunomodulators acting on p38α MAPK. Expand
p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening
TLDR
The use of target ensembles, rather than single conformations, resulted in a performance improvement in both the ability to reproduce experimental bound conformations and the capability of mining active molecules from compound libraries. Expand
In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
TLDR
This work chemically modified a substituted triazole-class lead compound to improve the binding affinity and selectivity via a "minimal decoration" strategy, which resulted in potent and selective kinase inhibitors against LCK and BTK. Expand
Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.
TLDR
An approach to the development of such inhibitors of p38α mitogen-activated protein (MAP) kinase on the basis of the highly selective molecular probe Skepinone-L is described, finding that introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compounds. Expand
Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine.
TLDR
By synthesizing 69 compounds, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Expand
An updated patent review of p38 MAP kinase inhibitors (2014-2019)
TLDR
P38 MAP kinase inhibitors are a mature field with many pre-clinically validated structural classes, more than 20 candidates in clinical trials but still (except the weak and unselective p38 inhibitor pirfenidone) no approved drug. Expand
Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.
TLDR
A kinase profiling experiment revealed a high degree of selectivity of designated p38α directed inhibitors although they target the ATP binding site that is largely conserved across the human kinome, which may cause a variety of diseases. Expand
Metabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole blood.
TLDR
Five series of metabolically stable disubstituted dibenzo[b,e]oxepin-11(6H)-ones were synthesized and tested in a p38α enzyme assay for their inhibition of tumor necrosis factor-α release in human whole blood and it has been shown that the additional introduction of hydrophilic residues at position 9 leads to a substantial improvement of the inhibitory potency and metabolic stability. Expand
A p38 Substrate-Specific MK2-EGFP Translocation Assay for Identification and Validation of New p38 Inhibitors in Living Cells: A Comprising Alternative for Acquisition of Cellular p38 Inhibition Data
TLDR
It is demonstrated that the MK2-EGFP translocation assay is a suitable primary screening approach for p38-MAPK drug development and provide an attractive labor- and cost saving alternative to other cell based methods including determination of cytokine release from hPBMCs or whole blood. Expand
Function, Structure and Topology of Protein Kinases
Protein kinases represent one of the most successful target classes for the development of new medicines. Because of their key roles in cellular signalling, kinases are stringently regulated by aExpand
...
1
2
3
...

References

SHOWING 1-10 OF 45 REFERENCES
p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.
TLDR
X-ray crystallographic analysis of p38-inhibitor complexes reinforces the observations made from site-directed mutagenesis studies, thereby providing a molecular basis for understanding the kinase selectivity of these inhibitors. Expand
Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
TLDR
The development of a new FLiK (Fluorescent Labels in Kinases) binding assay to detect small molecules that induce changes in the conformation of the glycine-rich loop and may be a useful alternative to develop direct binding assays for kinases that do not adopt the DFG-out conformation while also avoiding the use of expensive kits, detection reagents, or radioactivity frequently employed with activity-based assays. Expand
Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
TLDR
A structural bioinformatics approach was used to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge, and PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. Expand
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
TLDR
X-ray crystallography revealed that DP-802 and analogs induce an enhanced type II conformation upon binding to either the unphosphorylated or the doubly phosphorylated form of p38-alpha kinase. Expand
MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein
Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38alpha p38beta, p38gamma, andExpand
Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.
TLDR
This work undertook careful studies to definitively demonstrate that treatment with SB 203580 had no effect on Thr(180) and Tyr(182) phosphorylation, and hence activation of p38 in vivo, and clearly indicates that SB203580 specifically inhibits the activity of p 38 MAPK but not its activation by upstream MAPKK. Expand
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
TLDR
A fluorescence-based kinase binding assay for identifying and characterizing ligands which stabilize the inactive kinase conformation is developed and validation of this assay using the serine/threonine kinase p38alpha is presented. Expand
Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition
TLDR
The continued study of high-resolution structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins will in the long-term help in developing new low-molecular weight kinase inhibitors. Expand
Successful structure-based design of recent p38 MAP kinase inhibitors.
TLDR
This review will summarize current knowledge on p38 MAP kinase inhibitors and will critically discuss proceedings and strategies toward achieving selectivity and potency. Expand
Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
TLDR
Guided by complex crystal structures, the initially identified N-aryl, N'-thiazole urea scaffold was employed and introduced key structural elements that allowed the formation of novel hydrogen bonding interactions within the allosteric site of p38α, resulting in potent type III inhibitors. Expand
...
1
2
3
4
5
...